Phase I/II trial of outpatient PEG-interferon with interleukin-2 in advanced renal cell carcinoma: A cytokine working group study

Journal of Immunotherapy

Volumn 30, Issue 8, 2007, Pages 839-846

  Clark, Joseph I ^a   Mehrabi, Jessica ^a   Sosman, Jeffrey A ^b   Logan, Theodore F ^c   Margolin, Kim A ^d   Dutcher, Janice P ^e   Urba, Walter J ^f   Ernstoff, Marc S ^g   McDermott, David F ^h   Lau, Ann M ^a   Atkins, Michael B ^h  

^a LOYOLA UNIVERSITY HEALTH SYSTEM   (United States)

^b VANDERBILT UNIVERSITY   (United States)

^c INDIANA UNIVERSITY   (United States)

^d CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^e OUR LADY OF MERCY MEDICAL CENTER   (United States)

^f EARLE A CHILES RESEARCH INSTITUTE   (United States)

^g DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^h BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

CWG; Interleukin 2; PEG interferon; Phase I II; Renal cell carcinoma

Indexed keywords

ALPHA2B INTERFERON; INTERLEUKIN 2; POLYETHYLENE GLYCOL INTERFERON ALPHA 2B; UNCLASSIFIED DRUG;

ACUTE KIDNEY FAILURE; ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; AGED; ARTICLE; CARDIOMYOPATHY; CEREBRAL BLINDNESS; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DRUG CARCINOGENICITY; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESPONSE; DRUG SCREENING; DYSPNEA; EMBOLIC STROKE; FEMALE; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HUMAN; HYPOTENSION; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; MAXIMUM TOLERATED DOSE; MULTIPLE CYCLE TREATMENT; OUTPATIENT CARE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; TACHYCARDIA; TUMOR REGRESSION;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, RENAL CELL; CARDIOMYOPATHIES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; INTERFERON ALFA-2B; INTERLEUKIN-2; KIDNEY FAILURE, ACUTE; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; OUTPATIENTS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 37349102682     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/CJI.0b013e3181587977     Document Type: Article

References (26)

1. American Cancer Society. Cancer Facts and figures 2006. Atlanta: American Cancer Society; 2006.
2. Fyfe G, Fisher RI, Rosenberg SA, et al. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol. 1995;13:688-696.
3. Fisher RI, Rosenberg SA, Fyfe G. Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma. Cancer J Sci Am. 2000;6(suppl 1):S55-S57.
4. Negrier S, Escudier B, Lasset C, et al. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma: Groupe Francais d'Immunotherapie. N Engl J Med. 1998;338:1272-1278.
5. Minasian LM, Motzer RJ, Gluck L, et al. Interferon alfa-2a in advanced renal cell carcinoma: treatment results and survival in 159 patients with long-term follow-up. J Clin Oncol. 1993;11:368-1375.
6. Medical Research Council Renal Cancer Collaborators. Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomized controlled trial. Lancet. 1999;353:14-17.
7. Hernberg M, Pyrhonen S, Muhonen T. Regimens with or without interferon-alpha as treatment for metastatic melanoma and renal cell carcinoma: an overview of randomized trials. J Immunother. 1999;22:145-154.
8. Atzpodien J, Kirchner H, Hanninen EL, et al. Interleukin-2 in combination with interferon-alpha and 5-fluorouracil for metastatic renal cell cancer. Eur J Cancer. 1993;29A(suppl 5):S6-S8.
9. Coppin C, Porzsolt F, Awa A, et al. Immunotherapy for advanced renal cell carcinoma. Cochrane Database Syst Rev. 2005;1:CD001425.
10. Atzpodien J, Lopez Hanninen E, Kirchner H, et al. Multiinstitutional home-therapy trial of recombinant human interleukin-2 and interferon alfa-2 in progressive metastatic renal cell carcinoma. J Clin Oncol. 1995;13:497-501.
11. Figlin RA, Belldegrun A, Modawer N, et al. Concomitant administration of recombinant human interleukin-2 and recombinant interferon alfa-2A: an active outpatient regimen in metastatic renal cell carcinoma. J Clin Oncol. 1992;10:414-421.
12. Vogelzang NJ, Lipton A, Figlin RA. Subcutaneous interleukin-2 plus interferon alfa-2a in metastatic renal cancer: an outpatient multicenter trial. J Clin Oncol. 1993;11:1809-1816.
13. Dutcher JP, Fisher RI, Weiss G, et al. Outpatient subcutaneous interleukin-2 and alpha-interferon for metastatic renal cell cancer: five year follow-up of the Cytokine Working Group study. Cancer J Sci Am. 1997;3:157-162.
14. McDermott DF, Regan MM, Clark JI, et al. Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol. 2005;23:133-141.
15. Glue P, Fang JW, Rouzier-Panis R, et al. Pegylated interferon-α2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Hepatitis C Intervention Therapy Group. Clin Pharmacol Ther. 2000;68:556-567.
16. Zeuzem S, Feinman SV, Rasenack J, et al. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med. 2000;343:1666-1672.
17. Talpaz M, O'Brien S, Rose E, et al. Phase I study of polyethylene glycol formulation of interferon α-2b (Schering 54301) in Philadelphia chromosome-positive chronic myelogenous leukemia. Blood. 2001;98:1708-1713.
18. Bukowski R, Ernstoff MS, Gore ME, et al. Pegylated interferon alfa-2b treatment for patients with solid tumors: a phase I/II study. J Clin Oncol. 2002;20:3841-3949.
19. Motzer RJ, Rakhit A, Ginsberg M, et al. Phase I trial of 40-kd branched pegylated interferon alfa-2a for patients with advanced renal cell carcinoma. J Clin Oncol. 2001;19:1312-1319.
20. Yang JC, Sherry RM, Steinberg SM, et al. A randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cell cancer. J Clin Oncol. 2003;21:3127-3132.
21. Clark JI, Gollob J, Sosman J, et al. Phase I trial of polyethylene (PEG) interferon α-2b (IFN)+interleukin-2 (IL-2) in renal cell cancer (RCC). Proc Am Soc Clin Oncol. 2002;21:A2419.
22. Urba WJ, Seis RG, Longo DL, et al. Immunomodulatory properties and toxicity of interleukin 2 in patients with cancer. Cancer Res. 1990;50:185-192.
23. Motzer RJ, Mazumdar M, Bacik J, et al. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol. 1999;17:2530-2540.
24. Kirchner GI, Franzke A, Buer J, et al. Pharmacokinetics of recombinant human interleukin-2 in advanced renal cell carcinoma patients following subcutaneous application. Br J Clin Pharmacol. 1998;46:5-10.
25. Negrier S, Caty A, Lesimple T, et al. Treatment of patients with metastatic renal carcinoma with a combination of subcutaneous interleukin-2 and interferon alfa with or without fluorouracil. Groupe Francais d'Immunotherapie, Federation Nationale des Centres de Lutte Contre le Cancer. J Clin Oncol. 2000;18:4009-4015.
26. Dutcher JP, Logan T, Gordon M, et al. Phase II trial of interleukin-2, interferon-alpha, and 5-fluorouracil in metastatic renal cell cancer: a Cytokine Working Group Study. Clin Cancer Res. 2000;6:3442-3450.